Baseline gene expression in subcutaneous adipose tissue predicts diet-induced weight loss in individuals with obesity.

Autor:	Oghabian A; Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., van der Kolk BW; Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Marttinen P; Helsinki Institute for Information Technology HIIT, Department of Computer Science, Aalto University, Espoo, Finland., Valsesia A; Nestlé Institute of Health Sciences, Lausanne, Switzerland., Langin D; Department of Biochemistry, Toulouse University Hospitals, Toulouse, France.; Institut des Maladies Métaboliques et Cardiovasculaires, I2MC, Université de Toulouse, Inserm, Université Toulouse III-Paul Sabatier (UPS), Toulouse, France., Saris WH; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands., Astrup A; Healthy Weight Center, Novo Nordisk Fonden, Copenhagen, Denmark., Blaak EE; Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands., Pietiläinen KH; Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Healthy Weight Hub, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Jazyk:	angličtina
Zdroj:	PeerJ [PeerJ] 2023 Mar 24; Vol. 11, pp. e15100. Date of Electronic Publication: 2023 Mar 24 (Print Publication: 2023).
DOI:	10.7717/peerj.15100
Abstrakt:	Background: Weight loss effectively reduces cardiometabolic health risks among people with overweight and obesity, but inter-individual variability in weight loss maintenance is large. Here we studied whether baseline gene expression in subcutaneous adipose tissue predicts diet-induced weight loss success. Methods: Within the 8-month multicenter dietary intervention study DiOGenes, we classified a low weight-losers (low-WL) group and a high-WL group based on median weight loss percentage (9.9%) from 281 individuals. Using RNA sequencing, we identified the significantly differentially expressed genes between high-WL and low-WL at baseline and their enriched pathways. We used this information together with support vector machines with linear kernel to build classifier models that predict the weight loss classes. Results: Prediction models based on a selection of genes that are associated with the discovered pathways 'lipid metabolism' (max AUC = 0.74, 95% CI [0.62-0.86]) and 'response to virus' (max AUC = 0.72, 95% CI [0.61-0.83]) predicted the weight-loss classes high-WL/low-WL significantly better than models based on randomly selected genes ( P < 0.01). The performance of the models based on 'response to virus' genes is highly dependent on those genes that are also associated with lipid metabolism. Incorporation of baseline clinical factors into these models did not noticeably enhance the model performance in most of the runs. This study demonstrates that baseline adipose tissue gene expression data, together with supervised machine learning, facilitates the characterization of the determinants of successful weight loss. Competing Interests: At the time of the study, Armand Valsesia was a full-time employee at Nestlé Institute of Health Sciences SA. W. H. Saris discloses the receipt of research support from several food companies such as Nestlé, DSM, Unilever, Nutrition et Sante and Danone as well as pharmaceutical companies including GSK, Novartis and Novo Nordisk; he is also an unpaid scientific advisor for the International Life Science Institute (ILSI) Europe. Arne Astrup discloses grants and personal fees received from Gelesis, USA; personal fees from Acino, Switzerland; BioCare Copenhagen, DK; Dutch Beer Institute, NL; Groupe Éthique et Santé, France; IKEA Food Scientific Health Advisory Board, SE; McCain Foods Limited, USA; Navamedic, DK; Novo Nordisk, DK; Pfizer, USA; Saniona, DK; Weight Watchers, USA & Zaluvida, Switzerland; and grants from DC-Ingredients Denmark, which lie beyond the scope of the work reported here. Ellen E. Blaak received financial support from food industry, such as DSM, Danone, Friesland Campina, Avebe and Sensus, partly within the context of public–private consortia and has received funding from pharmaceutical companies including Novartis. She is involved in several task forces and expert groups related to ILSI Europe.g interests. (© 2023 Oghabian et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu